L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning

L-3,4-dihydroxyphenylalanine (L-DOPA) has been successfully used in the treatment of Parkinson’s disease (PD) for more than 50 years. It fulfilled the criteria to cross the blood–brain barrier and counteract the biochemical defect of dopamine (DA). It remarkably worked after some adjustments in line...

Descripción completa

Detalles Bibliográficos
Autores principales: Chagraoui, Abdeslam, Boulain, Marie, Juvin, Laurent, Anouar, Youssef, Barrière, Grégory, De Deurwaerdère, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981630/
https://www.ncbi.nlm.nih.gov/pubmed/31906250
http://dx.doi.org/10.3390/ijms21010294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981630/
https://www.ncbi.nlm.nih.gov/pubmed/31906250
http://dx.doi.org/10.3390/ijms21010294

Ejemplares similares